Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
复制标题
DOI：
10.1093/oncolo/oyac137
复制
发表时间：
2022-10-01
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
在外周T细胞淋巴瘤（PTCL）、皮肤T细胞淋巴瘤（CTCL）或B细胞非霍奇金淋巴瘤（NHL）患者的多项试验中评估了维布妥昔单抗（BV）（一种针对CD 30抗原的抗体-药物偶联物）的安全性和疗效。本研究的目的是探讨CD 30表达水平与BV临床反应之间的关系。我们分析了在复发性或难治性PTCL、CTCL或B细胞NHL的5项前瞻性临床研究中接受BV单药治疗的患者的缓解情况。使用Ber H2抗体通过免疫组织化学（IHC）评估275例患者的CD 30表达。在所有5项研究中，140例（50.9%）患者的肿瘤CD 30表达<10%，包括60例（21.8%）患者的IHC检测不到CD 30。在任何研究中，CD 30表达≥10%或<10%的患者之间的总体缓解率均无显著差异。在所有研究中，CD 30 ≥10%和<10%组的中位缓解持续时间也相似。在对一系列表达CD 30的淋巴瘤研究的分析中，通过标准IHC测量的单独CD 30表达不能预测BV的临床获益，使得表达阈值水平的确定不确定。维布妥昔单抗（一种针对CD 30抗原的抗体-药物偶联物）的安全性和疗效已在淋巴瘤患者的多项试验中进行了评估。本文研究了CD 30表达水平与维布妥昔单抗临床应答之间的关系。
The safety and efficacy of brentuximab vedotin (BV), an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell non-Hodgkin lymphoma (NHL). The objective of this research was to examine the relationship between CD30 expression level and clinical response to BV. We analyzed response in patients treated with BV monotherapy in 5 prospective clinical studies in relapsed or refractory PTCL, CTCL, or B-cell NHL. CD30 expression was assessed by immunohistochemistry (IHC) using the Ber H2 antibody for 275 patients. Across all 5 studies, 140 (50.9%) patients had tumors with CD30 expression <10%, including 60 (21.8%) with undetectable CD30 by IHC. No significant differences were observed for any study in overall response rates between patients with CD30 expression ≥10% or <10%. Median duration of response was also similar in the CD30 ≥10% and <10% groups for all studies. In this analysis of studies across a range of CD30-expressing lymphomas, CD30 expression alone, as measured by standard IHC, does not predict clinical benefit from BV, making the determination of a threshold level of expression uncertain. The safety and efficacy of brentuximab vedotin, an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with lymphoma. This article examines the relationship between CD30 expression level and clinical response to brentuximab vedotin.
登录
查看更多内容
影响因子：
45.3
作者：
Kim, Youn H.;Tavallaee, Mahkam;Horwitz, Steven M.
通讯作者：
Horwitz, Steven M.
影响因子：
20.3
作者：
Jacobsen, Eric D.;Sharman, Jeff P.;Bartlett, Nancy L.
通讯作者：
Bartlett, Nancy L.
影响因子：
20.3
作者：
Oflazoglu, Ezogelin;Stone, Ivan J.;Gerber, Hans-Peter
通讯作者：
Gerber, Hans-Peter
影响因子：
10.1
作者：
Mueller, Philipp;Martin, Kea;Zippelius, Alfred
通讯作者：
Zippelius, Alfred
影响因子：
20.3
作者：
Bossard, Celine;Dobay, Maria Pamela;de Leval, Laurence
通讯作者：
de Leval, Laurence